147 related articles for article (PubMed ID: 29359976)
1. Assessment of tissue-specific cortisol activity with regard to degeneration of the suspensory ligaments in horses with pituitary pars intermedia dysfunction.
Hofberger SC; Gauff F; Thaller D; Morgan R; Keen JA; Licka TF
Am J Vet Res; 2018 Feb; 79(2):199-210. PubMed ID: 29359976
[TBL] [Abstract][Full Text] [Related]
2. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.
Hart KA; Kitchings KM; Kimura S; Norton NA; Myrna KE
Am J Vet Res; 2016 Nov; 77(11):1236-1244. PubMed ID: 27805438
[TBL] [Abstract][Full Text] [Related]
3. Suspensory ligament degeneration associated with pituitary pars intermedia dysfunction in horses.
Hofberger S; Gauff F; Licka T
Vet J; 2015 Mar; 203(3):348-50. PubMed ID: 25641552
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction.
Morgan RA; Keen JA; Homer N; Nixon M; McKinnon-Garvin AM; Moses-Williams JA; Davis SR; Hadoke PWF; Walker BR
Endocrinology; 2018 Nov; 159(11):3791-3800. PubMed ID: 30289445
[TBL] [Abstract][Full Text] [Related]
5. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
McFarlane D; Holbrook TC
J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
[TBL] [Abstract][Full Text] [Related]
6. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
9. Whole-body phenylalanine kinetics and skeletal muscle protein signaling in horses with pituitary pars intermedia dysfunction.
Mastro LM; Adams AA; Urschel KL
Am J Vet Res; 2014 Jul; 75(7):658-67. PubMed ID: 24959733
[TBL] [Abstract][Full Text] [Related]
10. Influence of season and pituitary pars intermedia dysfunction on hair cortisol concentration in horses.
Banse HE; Getachew F; Levy M; Smits J
Domest Anim Endocrinol; 2020 Jul; 72():106375. PubMed ID: 31431311
[TBL] [Abstract][Full Text] [Related]
11. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
Mastro LM; Adams AA; Urschel KL
Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
[TBL] [Abstract][Full Text] [Related]
12. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
13. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
[TBL] [Abstract][Full Text] [Related]
14. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
15. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
McFarlane D; Cribb AE
Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
[TBL] [Abstract][Full Text] [Related]
16. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction.
Pease AP; Schott HC; Howey EB; Patterson JS
J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144
[TBL] [Abstract][Full Text] [Related]
17. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
[TBL] [Abstract][Full Text] [Related]
18. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
19. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.
McFarlane D; Miller LM; Craig LE; Dybdal NO; Habecker PL; Miller MA; Patterson JS; Cribb AE
Am J Vet Res; 2005 Dec; 66(12):2055-9. PubMed ID: 16379646
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
